50
Participants
Start Date
December 31, 2001
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Peginterferon alfa-2a with Ribavirin
Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients \>=75 kg) for 48 weeks
Peginterferon alfa-2a
Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH